

Donor 6508

Genetic Testing Summary

Fairfax Cryobank recommends reviewing this genetic testing summary with your healthcare provider to determine suitability.

Last Updated: 08/30/22

Donor Reported Ancestry: Irish, Norwegian, Croatian


Jewish Ancestry: No

Genetic Test*	Result	Comments/Donor's Residual
		Risk**

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by gene sequencing in the CFTR gene	1/440
Spinal Muscular Atrophy (SMA) carrier screening	Negative for deletions of exon 7 in the SMN1 gene	1/894
Expanded Genetic Disease Carrier Screening Panel attached- 283 diseases by gene sequencing	Negative for genes sequenced	

*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

**Donor residual risk is the chance the donor is still a carrier after testing negative.



Patient Information Name: Donor 6508 Date of Birth

Sema4 ID Client Indication: Carrier Screening

Specimen Information

Specimen Type: Blood Date Collected: 07/12/2021 Date Received: 07/13/2021 Final Report: 07/28/2021

Referring Provider

Fairfax Cryobank, Inc.



Expanded Carrier Screen (283) Minus TSE

Number of genes tested: 283

SUMMARY OF RESULTS AND RECOMMENDATIONS

⊖ Negative

Negative for all genes tested To view a full list of genes and diseases tested please see Table 1 in this report

AR=Autosomal recessive; XL=X-linked

Recommendations

- CGG repeat analysis of *FMR1* for fragile X syndrome is not performed on males as repeat expansion of premutation alleles is not expected in the male germline.
- Individuals of Asian, African, Hispanic and Mediterranean ancestry should also be screened for hemoglobinopathies by CBC and hemoglobin electrophoresis.
- Consideration of residual risk by ethnicity after a negative carrier screen is recommended for the other diseases on the panel, especially in the case of a positive family history for a specific disorder.

Test description

This patient was tested for a panel of diseases using a combination of sequencing, targeted genotyping and copy number analysis. Please note that negative results reduce but do not eliminate the possibility that this individual is a carrier for one or more of the disorders tested. Please see Table 1 for a list of genes and diseases tested, and **go.sema4.com/residualrisk** for specific detection rates and residual risk by ethnicity. With individuals of mixed ethnicity, it is recommended to use the highest residual risk estimate. Only variants determined to be pathogenic or likely pathogenic are reported in this carrier screening test.

Fat C. Nulle

Fatimah Nahhas-Alwan, Ph.D., DABMGG, Laboratory Director Laboratory Medical Consultant: George A. Diaz, M.D., Ph.D





Genes and diseases tested

For specific detection rates and residual risk by ethnicity, please visit **go.sema4.com/residualrisk**

Table 1: List of genes and diseases tested with detailed results

	Disease	Gene	Inheritance Pattern	Status	Detailed Summary
Θ	Negative				
	3-Beta-Hydroxysteroid Dehydrogenase Type II Deficiency	HSD3B2	AR	Reduced Risk	
	3-Methylcrotonyl-CoA Carboxylase Deficiency (<i>MCCC1</i> -Related)	MCCC1	AR	Reduced Risk	
	3-Methylcrotonyl-CoA Carboxylase Deficiency (<i>MCCC2</i> -Related)	MCCC2	AR	Reduced Risk	
	3-Methylglutaconic Aciduria, Type III	OPA3	AR	Reduced Risk	
	3-Phosphoglycerate Dehydrogenase Deficiency	PHGDH	AR	Reduced Risk	
	6-Pyruvoyl-Tetrahydropterin Synthase Deficiency	PTS	AR	Reduced Risk	
	Abetalipoproteinemia	MTTP	AR	Reduced Risk	
	Achromatopsia (CNGB3-related)	CNGB3	AR	Reduced Risk	
	Acrodermatitis Enteropathica	SLC39A4	AR	Reduced Risk	
	Acute Infantile Liver Failure	TRMU	AR	Reduced Risk	
	Acyl-CoA Oxidase Deficiency	ACOX1	AR	Reduced Risk	
	Adenosine Deaminase Deficiency	ADA	AR	Reduced Risk	
	Adrenoleukodystrophy, X-Linked	ABCD1	XL	Reduced Risk	
	Aicardi-Goutieres Syndrome (SAMHD1-Related)	SAMHD1	AR	Reduced Risk	
	Alpha-Mannosidosis	MAN2B1	AR	Reduced Risk	
	Alpha-Thalassemia	HBA1/HBA2	AR	Reduced Risk	HBA1 Copy Number: 2 HBA2 Copy Number: 2 No pathogenic copy number variants detected HBA1/ HBA2 Sequencing: Negative
	Alpha-Thalassemia Intellectual Disability Syndrome	ATRX	XL	Reduced Risk	
	Alport Syndrome (COL4A3-Related)	COL4A3	AR	Reduced Risk	
	Alport Syndrome (COL4A4-Related)	COL4A4	AR	Reduced Risk	
	Alport Syndrome (COL4A5-Related)	COL4A5	XL	Reduced Risk	
	Alstrom Syndrome	ALMS1	AR	Reduced Risk	
	Andermann Syndrome	SLC12A6	AR	Reduced Risk	
	Argininosuccinic Aciduria	ASL	AR	Reduced Risk	
	Aromatase Deficiency	CYP19A1	AR	Reduced Risk	
	Arthrogryposis, Mental Retardation, and Seizures	SLC35A3	AR	Reduced Risk	
	Asparagine Synthetase Deficiency	ASNS	AR	Reduced Risk	
	Aspartylglycosaminuria	AGA	AR	Reduced Risk	
	Ataxia With Isolated Vitamin E Deficiency	TTPA	AR	Reduced Risk	
	Ataxia-Telangiectasia	ATM	AR	Reduced Risk	
	Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay	SACS	AR	Reduced Risk	
	Bardet-Biedl Syndrome (BBS10-Related)	BBS10	AR	Reduced Risk	
	Bardet-Biedl Syndrome (BBS12-Related)	BBS12	AR	Reduced Risk	
	Bardet-Biedl Syndrome (<i>BBS1</i> -Related)	BBS1	AR	Reduced Risk	
	Bardet-Biedl Syndrome (BBS2-Related)	BBS2	AR	Reduced Risk	
	Bare Lymphocyte Syndrome, Type II	CIITA	AR	Reduced Risk	
	Bartter Syndrome, Type 4A	BSND	AR	Reduced Risk	
	Bernard-Soulier Syndrome, Type A1	GP1BA	AR	Reduced Risk	
	Bernard-Soulier Syndrome, Type C	GP9	AR	Reduced Risk	
	Beta-Globin-Related Hemoglobinopathies	HBB	AR	Reduced Risk	
	Beta-Ketothiolase Deficiency	ACAT1	AR	Reduced Risk	



Carrier screening report Donor 6508 Date of Birth: Sema4 ID:

Bilateral Frontoparietal Polymicrogyria	GPR56	AR	Reduced Risk	
Biotinidase Deficiency	BTD	AR	Reduced Risk	
Bloom Syndrome	BLM	AR	Reduced Risk	
Canavan Disease	ASPA	AR	Reduced Risk	
Carbamoylphosphate Synthetase I Deficiency	CPS1	AR	Reduced Risk	
Carnitine Palmitoyltransferase IA Deficiency	CPT1A	AR	Reduced Risk	
Carnitine Palmitoyltransferase II Deficiency	CPT2	AR	Reduced Risk	
Carpenter Syndrome	RAB23	AR	Reduced Risk	
Cartilage-Hair Hypoplasia	RMRP	AR	Reduced Risk	
Cerebral Creatine Deficiency Syndrome 1	SLC6A8	XL	Reduced Risk	
Cerebral Creatine Deficiency Syndrome 2	GAMT	AR	Reduced Risk	
Cerebrotendinous Xanthomatosis	CYP27A1	AR	Reduced Risk	
	NDRG1	AR		
Charcot-Marie-Tooth Disease, Type 4D	NDRGI	AR	Reduced Risk	
Charcot-Marie-Tooth Disease, Type 5 / Arts Syndrome	PRPS1	XL	Reduced Risk	
Charcot-Marie-Tooth Disease, X-Linked	GJB1	XL	Reduced Risk	
Choreoacanthocytosis	VPS13A	AR	Reduced Risk	
Choroideremia	СНМ	XL	Reduced Risk	
Chronic Granulomatous Disease (CYBA-Related)	СҮВА	AR	Reduced Risk	
Chronic Granulomatous Disease (CYBB-Related)	CYBB	XL	Reduced Risk	
Citrin Deficiency	SLC25A13	AR	Reduced Risk	
Citrullinemia, Type 1	ASS1	AR	Reduced Risk	
Cohen Syndrome	VPS13B	AR	Reduced Risk	
Combined Malonic and Methylmalonic Aciduria	ACSF3	AR	Reduced Risk	
Combined Oxidative Phosphorylation Deficiency	-			
1	GFM1	AR	Reduced Risk	
Combined Oxidative Phosphorylation Deficiency 3	TSFM	AR	Reduced Risk	
Combined Pituitary Hormone Deficiency 2	PROP1	AR	Reduced Risk	
Combined Pituitary Hormone Deficiency 3	LHX3	AR	Reduced Risk	
Combined SAP Deficiency	PSAP	AR	Reduced Risk	
,			no da oc a mon	
Congenital Adrenal Hyperplasia due to 17-	CYP17A1	AR	Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21-	CYP17A1 CYP21A2			<i>CYP21A2</i> copy number: 2 <i>CYP21A2</i> sequencing: Negative
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency	-	AR	Reduced Risk	<i>CYP21A2</i> copy number: 2 <i>CYP21A2</i> sequencing: Negative
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia	CYP21A2	AR AR	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type Ia	CYP21A2 MPL	AR AR AR	Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type Ib	CYP21A2 MPL PMM2	AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc	CYP21A2 MPL PMM2 MPI	AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type Ia Congenital Disorder of Glycosylation, Type Ib	CYP21A2 MPL PMM2 MPI ALG6 NTRK1	AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type Ia Congenital Disorder of Glycosylation, Type Ib Congenital Disorder of Glycosylation, Type Ic Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related)	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE	AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type Ia Congenital Disorder of Glycosylation, Type Ib Congenital Disorder of Glycosylation, Type Ic Congenital Disorder of Glycosylation, Type Ic Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Myasthenic Syndrome (RAPSN- Related)	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN	AR AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type Ia Congenital Disorder of Glycosylation, Type Ib Congenital Disorder of Glycosylation, Type Ic Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Myasthenic Syndrome (RAPSN- Related) Congenital Neutropenia (HAX1-Related)	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1	AR AR AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>RAPSN</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related)	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45	AR AR AR AR AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>RAPSN</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11	AR AR AR AR AR AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>RAPSN</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Neutrof Glycosylation, Type lc Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Neusritivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystinosis	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Neusritivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Neutropenia (HAX1-Related) Congenital Neutropenia (VPS45-Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Neusroitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>RAPSN</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1 DMD RTEL1	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Neusrbitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>RAPSN</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy Dyskeratosis Congenita (<i>RTEL1</i> -Related)	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1 DMD RTEL1 COL7A1	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>RAPSN</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy Dyskeratosis Congenita (<i>RTEL1</i> -Related) Dystrophic Epidermolysis Bullosa Ehlers-Danlos Syndrome, Type VIIC	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1 DMD RTEL1 COL7A1 ADAMTS2	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Neuropenia (Charner Related) Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Neutropenia (HAX1-Related) Congenital Neutropenia (VPS45-Related) Congenital Neutropenia (VPS45-Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy Dyskeratosis Congenita (RTEL1-Related) Dystrophic Epidermolysis Bullosa Ehlers-Danlos Syndrome, Type VIIC Ellis-van Creveld Syndrome (EVC-Related)	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1 DMD RTEL1 COL7A1 ADAMTS2 EVC	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Neuropenia (Changer Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (CHRNE- Related) Congenital Neutropenia (HAX1-Related) Congenital Neutropenia (HAX1-Related) Congenital Neutropenia (VP545-Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy Dyskeratosis Congenita (RTEL1-Related) Dystrophic Epidermolysis Bullosa Ehlers-Danlos Syndrome (EVC-Related) Emery-Dreifuss Myopathy 1	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1 DMD RTEL1 COL7A1 ADAMTS2 EVC EMD	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Disorder of Glycosylation, Type lc Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Myasthenic Syndrome (<i>RAPSN</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy Dyskeratosis Congenita (<i>RTEL1</i> -Related) Dystrophic Epidermolysis Bullosa Ehlers-Danlos Syndrome (<i>EVC</i> -Related) Emery-Dreifuss Myopathy 1 Enhanced S-Cone Syndrome	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1 DMD RTEL1 COL7A1 ADAMTS2 EVC EMD NR2E3	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	
Congenital Adrenal Hyperplasia due to 17- Alpha-Hydroxylase Deficiency Congenital Adrenal Hyperplasia due to 21- Hydroxylase Deficiency Congenital Amegakaryocytic Thrombocytopenia Congenital Disorder of Glycosylation, Type la Congenital Disorder of Glycosylation, Type lb Congenital Disorder of Glycosylation, Type lc Congenital Insensitivity to Pain with Anhidrosis Congenital Insensitivity to Pain with Anhidrosis Congenital Myasthenic Syndrome (<i>CHRNE</i> - Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>HAX1</i> -Related) Congenital Neutropenia (<i>VPS45</i> -Related) Corneal Dystrophy and Perceptive Deafness Corticosterone Methyloxidase Deficiency Cystic Fibrosis Cystinosis D-Bifunctional Protein Deficiency Deafness, Autosomal Recessive 77 Duchenne Muscular Dystrophy / Becker Muscular Dystrophy Dyskeratosis Congenita (<i>RTEL1</i> -Related) Dystrophic Epidermolysis Bullosa Ehlers-Danlos Syndrome (<i>EVC</i> -Related) Emery-Dreifuss Myopathy 1	CYP21A2 MPL PMM2 MPI ALG6 NTRK1 CHRNE RAPSN HAX1 VPS45 SLC4A11 CYP11B2 CFTR CTNS HSD17B4 LOXHD1 DMD RTEL1 COL7A1 ADAMTS2 EVC EMD	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk	



Factor XI Descince Fit AR Produced Rate Mypercholasterolemia KRAPA AR Reduced Rate Familia Lipsacholasterolemia KRAPA AR Reduced Rate Familia Lipsacholasterolemia LOL RAP AR Reduced Rate Familia Lipsacholasterolemia LOL R AR Reduced Rate Familia Lipsacholasterolemia LOL R AR Reduced Rate Familia Lipsacholasterolemia KCNJII AR Reduced Rate Familia Lipsacholasterolemia KCNJII AR Reduced Rate Fanconi Ameria, Group C MACC AR Reduced Rate Fraconi Ameria, Group C MACC AR Reduced Rate Fraconi Ameria, Group C MACC AR Reduced Rate Fraconi Ameria, Group C MAC Reduced Rate Fraconica Rate GACLE Syndeme FM AR Reduced Rate Galactosemia GAL AR Reduced Rate Galactosemia GAL AR Reduced Rate Galactosemia GAL </th <th>Factor IX Deficiency</th> <th>Fg</th> <th>XL</th> <th>Reduced Risk</th> <th></th>	Factor IX Deficiency	Fg	XL	Reduced Risk	
Hypercholesterolemia (J.B. RAPH A.R. Produced Resk Familal Dysacholesterolemia LDLR A.R. Reduced Resk Familal Dysacholesterolemia LDLR A.R. Reduced Resk Familal Dysacholesterolemia LDLR A.R. Reduced Resk Familal Dysacholesterolemia REXVL31 A.R. Reduced Resk Familal Dysacholesterolemia REXVL31 A.R. Reduced Resk Fameonia Anemia, Group C FAN/CC A.R. Reduced Resk Graduat Systemore G/S.H. A.R. Reduced Resk <	Factor XI Deficiency	F11	AR	Reduced Risk	
Familia Typercholesterolemia LDH AB Enducid Field Familia Typerinsultinium (XCP/Lax Related) RCC/DI AB Reduced Field Familia Typerinsultinium (XCP/Lax Related) RC/DII AB Reduced Field Familia Mediterranean (Scoup A //ACA AB Reduced Field Francol Amenia, Group C //ACA AB Reduced Field Fragle X Syndrome FMR RCG AR Reduced Risk Fragle X Syndrome FM AR Reduced Risk FMR: COD reped splate Note Provide and the Provide and the String as the pather here previously tested of is a menological data splate and the String as the pather here previously tested of a far menological data splate Action and the String as the pather here previously tested of is a menological data splate and the String as the pather here previously tested of a far menological data splate and tested field Glactard Actional Syndrome SL_2AAJ AR Reduced Field Glactar Actidemin, Type In GAA <		LDLRAP1	AR	Reduced Risk	
Familia Typerinsularium (IACCEP Related) AICCE AP Reduced Risk Familia Modiferranes Four METY AP Reduced Risk Familia Modiferranes Four METY AP Reduced Risk Familia Modiferranes Four METY AP Reduced Risk Fanceria Anemia, Group C FANCC AP Reduced Risk Fanceria Anemia, Group C FANCC AP Reduced Risk Fraglic X Syndrome FME Reduced Risk Fraglic X Composition Notes Note Representation Notes Notes Representation Notes Notes Representation Notes Notes Representation Notes Representatio Notes Representation Notes Representation Notes Representation N	Familial Dysautonomia	IKBKAP	AR	Reduced Risk	
Familal Hyperinsultinem (KCM/L2):Related KCM/L1 AP Peduced Fiels Fancen Annema, Group A FAVICA AP Peduced Fiels Fancen Annema, Group G FAVICA AP Peduced Fiels Francen Annema, Group G FAVICA AP Peduced Fiels Francen Annema, Group G FAVICA AP Peduced Fiels Fragite X Syndrome FWR1 XL Reduced Fiels Fragite X Syndrome FWR1 XL Reduced Fiels Fragite X Syndrome FW AP Reduced Fiels Galactokinaso Deficiency GALIX AP Reduced Fiels Galact	Familial Hypercholesterolemia	LDLR	AR	Reduced Risk	
Familal Mediterranean Favor MEP/ AB Reduced Risk Fancerial Anemia, Group G FANCA AB Reduced Risk Francerial Anemia, Group G FANCA AB Reduced Risk Fragile X Syndrome FAMIC AR Reduced Risk GRACLE Syndrome and Other BCSL-Related BCSL AR Reduced Risk Graduationase Deficiency GAL AR Reduced Risk Galactostemia	Familial Hyperinsulinism (ABCC8-Related)	ABCC8	AR	Reduced Risk	
Fancel Anemia, Group A FAVCA AR Reduced Rek Fancent Anemia, Group C FAVCG AR Reduced Rek Fracent Anemia, Group C FAVCG AR Reduced Rek Fracent Anemia, Group C FAVCG AR Reduced Rek Fragile X Syndrome FMD Status FMD Francest Anemia, Group A FMD XL Reduced Rek Francest Anemia, Group A FMD XL Reduced Rek Francest Anemia, Group A FMD AR Reduced Rek GRACLE Syndrome and Other GCSUL-Related ICCSU AR Reduced Rek Galactorianse Deficiency GALM AR Reduced Rek Galactorianse Deficiency	Familial Hyperinsulinism (KCNJ11-Related)	KCNJ11	AR	Reduced Risk	
Fancerial Anemia, Group C FANCE AP Reduced Risk Francel Anemia, Group G FANCE AR Reduced Risk Fragite XSyndrome FMR: XL Reduced Risk GRACLE Syndrome and Other BCSL-Related BCSL AR Reduced Risk Galactosemia GAL/ AR Reduced Risk Gularia Acidemia Type I GCDH AR Reduced Risk Gularia Acidemia Type I GCDH AR Reduced Risk Gularia Acidemia Type II GCDH AR Reduced Risk Gularia Acidemia Type II GCDH AR Reduced Risk	Familial Mediterranean Fever	MEFV	AR	Reduced Risk	
Fanceni Anemia Group G FANCG AR Reduced Risk Fragile XSyndrome FMI1 CGC repeat sizes: Not Performed FMI1 CGC repeat sizes: Not Performed was not performed af this time, as the patier has ether been prevously tested or is a model GALLE Syndrome and Other <i>RCSLL</i> -Related Biordern AR Reduced Risk GALLE Syndrome and Other <i>RCSLL</i> -Related Biordern BCSLL AR Reduced Risk Galactosimas Deficiency GAL/S AR Reduced Risk Galactosimas Deficiency GAL/S AR Reduced Risk Galactosimas Syndrome SC/28/3 AR Reduced Risk Galactosima Type II GCDH AR Reduced Risk Galactosima Syndrome SC/28/3 AR Reduced Risk Galactorina Type II GCDH AR Reduced Risk Galactorina Type II GCDH AR Reduced Risk Gycine Encephalopathy (AUCR-Related) AUT AR Reduced Risk Gycine Encephalopathy (AUCR-Related) GLDC AR Reduced Risk Gycine Encephalopathy (AUCR-Related) GLDC AR Reduced Risk Gycopen Storage Disease, Type II	Fanconi Anemia, Group A	FANCA	AR	Reduced Risk	
Fragic X Syndrome FMRI XL Reduced Risk FMRI Sequencing Synaphie Fragic X Syndrome FM AR Reduced Risk Fragic X CGG Fip001 repost separison testify the path separation testify thesparation testify the path sepath separatio	Fanconi Anemia, Group C		AR		
Fragile XSyndrome FMFI XL Reduced Risk FMFI Funance Deficiency F/H AR Reduced Risk GRACLE Syndrome and Other <i>BCSLL</i> -Related <i>BCSLL</i> AR Reduced Risk Glactorkinnes and Other <i>BCSLL</i> -Related <i>BCSLL</i> AR Reduced Risk Glactorkinnes and Other <i>BCSLL</i> -Related <i>BCSLL</i> AR Reduced Risk Glactorkinnes DPficiency GAL/I AR Reduced Risk Glactorkinnes DPficiency GAL/I AR Reduced Risk Glactorkinnes Obter (Encry) GAL/I AR Reduced Risk Glactorkinnes Obter (Encry) GAL/I AR Reduced Risk Glataria Acidemia Type I GCC/H AR Reduced Risk Glataria Acidemia Type II GCC/H AR Reduced Risk Glataria Acidemia Type II GCC/H AR Reduced Risk Glataria Acidemia Type II GCC/H AR Reduced Risk Glocogen Storage Disease, Type II GAA AR Reduced Risk Glycogen Storage Disease, Type II GAA	Fanconi Anemia, Group G	FANCG	AR	Reduced Risk	
CIRACUE Syndhome and Other BCSUL-Related BCSUL AR Reduced Risk Galactokinase Deficiency GALK0 AR Reduced Risk Galactokinase Deficiency GALK0 AR Reduced Risk Galactokinase Deficiency GALK0 AR Reduced Risk Galactokinase Deficiency GAL AR Reduced Risk Galactokinase Deficiency GALA AR Reduced Risk Galactokinase Deficiency GALA AR Reduced Risk Galactokinase Deficiency AR Reduced Risk Galactokinase Galactokinase Deficiency AR Reduced Risk Galactokinase Galactokinase Defisions, Type II GAL AR Reduced Risk Galycoen Encephalopathy (AUT-Related) GLDC AR Reduced Risk Glycogen Storage Disease, Type II GAL AR Reduced Risk Glycogen Storage Disease, Type II GAL AR Reduced Risk Glycogen Storage Disease, Type II GAL AR Reduced Risk Glycogen Storage Disease, Type II GAL AR	Fragile X Syndrome	FMR1	XL	Reduced Risk	FMR1 Sequencing: Negative Fragile X CGG triplet repeat expansion testir was not performed at this time, as the patier
Disorders' EL.S.JL AR Reduced Risk Galactokinas Deficincy GLLK AR Reduced Risk Galactokinas Deficincy GLLX AR Reduced Risk Galactokinas Open SLCARA AR Reduced Risk Galactokinas Type I GCDH AR Reduced Risk Glutaric Acidemia. Type I GCDH AR Reduced Risk Glutaric Acidemia. Type IL ETFA AR Reduced Risk Glutaric Acidemia. Type IL ETFDH AR Reduced Risk Glutaric Acidemia. Type IL ETFDH AR Reduced Risk Glychen Encephalopathy (GLDc-Related) GLDC AR Reduced Risk Glycogen Storage Disease. Type IL GAA AR Reduced Risk Glycogen Storage Disease. Type IL GAA AR Reduced Risk Glycogen Storage Disease. Type IL GAA AR Reduced Risk Glycogen Storage Disease. Type IL GBC AR Reduced Risk Glycogen Storage Disease. Type IL GBC AR Reduced Risk Glycogen Storage Disease. Type IL PTRM AR Reduced Risk Glycogen Storage Disease. Type IL PTRM AR Reduced Risk Glycogen Storage Disease. Type IL PTRM </td <td>Fumarase Deficiency</td> <td>FH</td> <td>AR</td> <td>Reduced Risk</td> <td></td>	Fumarase Deficiency	FH	AR	Reduced Risk	
Galactosemia CALT AR Reduced Risk Gaucher Disease GBA AR Reduced Risk Gittaria Ayndrome SLC2A3 AR Reduced Risk Gittaria Acidemia, Type I GCDH AR Reduced Risk Gittaria Acidemia, Type I GCDH AR Reduced Risk Gittaria Acidemia, Type II GA AR Reduced Risk Glycine Encephalopathy (LDC-Related) AMT AR Reduced Risk Glycogen Storage Disease, Type II GAA AR Reduced Risk Glycogen Storage Disease, Type II GAA AR Reduced Risk Glycogen Storage Disease, Type II GAA AR Reduced Risk Glycogen Storage Disease, Type IA GB/C AR Reduced Risk Glycogen Storage Disease, Type IA GB/C AR Reduced Risk Glycogen Storage Disease, Type IA GB/C AR Reduced Risk Glycogen Storage Disease, Type IA GB/C AR Reduced Risk Glycogen Storage Disease, Type IA GB/C AR Reduced Risk	•	BCS1L	AR	Reduced Risk	
Gaucher Disease GBA AR Reduced Risk Gitelman Syndrome SL C2M2 AR Reduced Risk Gituria Acidemia, Type IIa ETFA AR Reduced Risk Gutaria Acidemia, Type IIa ETFA AR Reduced Risk Glycine Encephalopathy (AMT-Related) AMT AR Reduced Risk Glycene Encephalopathy (AMT-Related) GLDC AR Reduced Risk Glycegen Storage Disease, Type II GAA AR Reduced Risk Glycegen Storage Disease, Type II GAB AR Reduced Risk Glycegen Storage Disease, Type II GBP AR Reduced Risk Glycegen Storage Disease, Type II GBP AR Reduced Risk Glycegen Storage Disease, Type ID SL C374_4 AR Reduced Risk Glycegen Storage Disease, Type ID SL C374_4 AR Reduced Risk Glycegen Storage Disease, Type IV PVCM AR Reduced Risk HoreCoA Lyase Disease, Type I PVCM AR Reduced Risk Hereditary Fuctose Intoterance ALDDB AR<	Galactokinase Deficiency	GALK1	AR	Reduced Risk	
Gitelman Syndrome SL C12A3 AR Reduced Risk Gutaric Acidemia, Type II CDH AR Reduced Risk Gutaric Acidemia, Type IIa ETFA AR Reduced Risk Glutaric Acidemia, Type IIa ETFDH AR Reduced Risk Glycine Encephalopathy (LDC-Related) AMT AR Reduced Risk Glyceine Storage Disease, Type II GAA AR Reduced Risk Glycogen Storage Disease, Type III AGA AR Reduced Risk Glycogen Storage Disease, Type III GAA AR Reduced Risk Glycogen Storage Disease, Type III GAA AR Reduced Risk Glycogen Storage Disease, Type III GAA AR Reduced Risk Glycogen Storage Disease, Type II GAC AR Reduced Risk Glycogen Storage Disease, Type II SL C3744 AR Reduced Risk Glycogen Storage Disease, Type II SL C3744 AR Reduced Risk Glycogen Storage Disease, Type II PKM AR Reduced Risk HMG-CAA Lysse Deficiency HMGCL AR Reduced Risk HMG-CAA Lysse Deficiency <td< td=""><td>Galactosemia</td><td>GALT</td><td>AR</td><td>Reduced Risk</td><td></td></td<>	Galactosemia	GALT	AR	Reduced Risk	
Calutaric Acidemia, Type I CCDH AR Reduced Risk Calutaric Acidemia, Type IIa ETFA AR Reduced Risk Calutaric Acidemia, Type IIa ETFA AR Reduced Risk Clycine Encephalopathy (AMT-Related) AMT AR Reduced Risk Clycine Encephalopathy (CLOC-Related) CLDC AR Reduced Risk Clycogen Storage Disease, Type II GAA AR Reduced Risk Clycogen Storage Disease, Type II AGL AR Reduced Risk Clycogen Storage Disease, Type II GGAA AR Reduced Risk Clycogen Storage Disease, Type II GGPC AR Reduced Risk Clycogen Storage Disease, Type ID SL/C37A4 AR Reduced Risk Clycogen Storage Disease, Type ID SL/C37A4 AR Reduced Risk Clycogen Storage Disease, Type VII PFRM AR Reduced Risk HMCCAL Lass Deficiency HMCCL AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Spactic Paraparesis 49	Gaucher Disease	GBA	AR	Reduced Risk	
Clutaric Acidemia, Type IIa ETFA AR Reduced Risk Clutaric Acidemia, Type IIa ETFDH AR Reduced Risk Clycine Encephalopathy (AD/R-Related) ANT AR Reduced Risk Clycogen Storage Disease, Type II CAA AR Reduced Risk Clycogen Storage Disease, Type II CAA AR Reduced Risk Clycogen Storage Disease, Type II CAC AR Reduced Risk Clycogen Storage Disease, Type II CAC AR Reduced Risk Clycogen Storage Disease, Type II CAC AR Reduced Risk Clycogen Storage Disease, Type IV Adut CBE AR Reduced Risk Clycogen Storage Disease, Type ID SLC37A4 AR Reduced Risk Clycogen Storage Disease, Type ID SLC37A4 AR Reduced Risk HMC-Co Lyase Deficiency HMGCL AR Reduced Risk HMC-Co Lyase Deficiency HMGCL AR Reduced Risk Herratsky-Puclak Syndrome, Type 1 HPS3 AR Reduced Risk Herratsky-Puclak Syndrome, Type 1 HPS3 AR Reduced Risk Herratsky-P	Gitelman Syndrome	SLC12A3	AR	Reduced Risk	
Glutaric Acidemia, Type IIC ETFDH AR Reduced Risk Gycine Encephalopathy (LMT-Related) ANT AR Reduced Risk Gycine Encephalopathy (LMC-Related) GLDC AR Reduced Risk Glycogen Storage Disease, Type II GAA AR Reduced Risk Glycogen Storage Disease, Type II GAA AR Reduced Risk Glycogen Storage Disease, Type IV Adult GBE1 AR Reduced Risk Glycogen Storage Disease, Type IV Dybl SLC37M AR Reduced Risk Glycogen Storage Disease, Type IV PVIM AR Reduced Risk Glycogen Storage Disease, Type IV PVIM AR Reduced Risk HMGCL AR Reduced Risk HMGCL AR Hemochromatosis, Type 2 HTR2 AR Reduced Risk Hemochromatosis, Type 3 TTR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Fructose I	Glutaric Acidemia, Type I	GCDH	AR	Reduced Risk	
Citycine Encephalopathy (AM7-Related) AMT AR Reduced Risk Citycine Encephalopathy (GLDC-Related) GLDC AR Reduced Risk Citycogen Storage Disease, Type II GAA AR Reduced Risk Citycogen Storage Disease, Type II AGL AR Reduced Risk Citycogen Storage Disease, Type IV / Adult GBE1 AR Reduced Risk Citycogen Storage Disease, Type IA GEPC AR Reduced Risk Citycogen Storage Disease, Type ID SLC37A4 AR Reduced Risk Citycogen Storage Disease, Type ID SLC37A4 AR Reduced Risk Citycogen Storage Disease, Type V PYGM AR Reduced Risk MiG-CoA Lyase Deficiency HIMGCL AR Reduced Risk HMG-CoA Lyase Deficiency HIMGCL AR Reduced Risk Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HFS1 AR Reduced Risk Hero	Glutaric Acidemia, Type IIa	ETFA	AR	Reduced Risk	
Citycine Encephalopathy (GLDC-Related) GLDC AR Reduced Risk Citycogen Storage Disease, Type II GAA AR Reduced Risk Citycogen Storage Disease, Type II GAL AR Reduced Risk Citycogen Storage Disease, Type II GBE: AR Reduced Risk Citycogen Storage Disease, Type II GBC AR Reduced Risk Citycogen Storage Disease, Type Ia GBPC AR Reduced Risk Citycogen Storage Disease, Type V PYGM AR Reduced Risk Citycogen Storage Disease, Type VI PYGM AR Reduced Risk MIMG-CoA Lyase Deficiency HMCL AR Reduced Risk Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Fructose Intolerance MLCS AR Reduced Risk Heroditary Stordrome, Type 3<	Glutaric Acidemia, Type IIc	ETFDH	AR	Reduced Risk	
Glycogen Storage Disease. Type II GAA AR Reduced Risk Glycogen Storage Disease. Type II AGL AR Reduced Risk Glycogen Storage Disease. Type IV / Adult GBE: AR Reduced Risk Glycogen Storage Disease. Type IV / Adult GBE: AR Reduced Risk Glycogen Storage Disease. Type IV GAP AR Reduced Risk Glycogen Storage Disease. Type IV PYGM AR Reduced Risk Glycogen Storage Disease. Type V PYGM AR Reduced Risk MMC-CoA Lyase Deficiency HMCCL AR Reduced Risk Hemochromatosis. Type 2A HFE2 AR Reduced Risk Hemochromatosis. Type 3 TFR2 AR Reduced Risk Hereditary Tuctose Intolerance ALDOB AR Reduced Risk Hermansky-Pudlak Syndrome. Type 1 HFS3 AR Reduced Risk Helmansky-Pudlak Syndrome. Type 3 HFS3 AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria (CBF-Related) CBS AR Reduced Risk Homocystinuria (CBF-Related)	Glycine Encephalopathy (AMT-Related)				
Citycogen Storage Disease, Type III AGL AR Reduced Risk Citycogen Storage Disease, Type IV Adut GBE1 AR Reduced Risk Citycogen Storage Disease, Type Ia GBPC AR Reduced Risk Citycogen Storage Disease, Type Ia GBPC AR Reduced Risk Citycogen Storage Disease, Type VI PYCM AR Reduced Risk Citycogen Storage Disease, Type VI PFKM AR Reduced Risk Citycogen Storage Disease, Type VI PFKM AR Reduced Risk HMG-CoA Lyase Deficiency HMGCL AR Reduced Risk Hemochromatosis, Type 2 TE2 AR Reduced Risk Hemochromatosis, Type 3 TE2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Honocrystinuria (CDS-Related) CDS AR Reduced Risk Homocystinuria (CDS-Related) CDS AR Reduced Risk Homocystinuria, cube Type MTRR AR Reduced Risk Hypohidrotic Ectodermal Dysp					
Citycogen Storage Disease, Type IV / Adult GBE1 AR Reduced Risk Otygucosan Body Disease CGPC AR Reduced Risk Glycogen Storage Disease, Type Ia GGPC AR Reduced Risk Glycogen Storage Disease, Type Ib SLC37A4 AR Reduced Risk Glycogen Storage Disease, Type V PYGM AR Reduced Risk HMG-CoA Lyase Deficiency HMGCL AR Reduced Risk HMG-CoA Lyase Deficiency HMGCL AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hemansky-Pudlak Syndrome, Type 1 HPS3 AR Reduced Risk Homocystinuria due to MTH/R Deficiency HTHR AR Reduced Risk Homocystinuria due to MTH/R Deficiency MTHR AR Reduced Risk Homocystinuria, CBE Type MTRR AR Reduced Risk Homocystinuria, CBE Type MTRR AR Reduced Risk Hyporhidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk					
Polyglucosan Body Disease CaB21 Ark Reduced Risk Glycogen Storage Disease, Type Ia CBP2 AR Reduced Risk Glycogen Storage Disease, Type IV SLC23744 AR Reduced Risk Glycogen Storage Disease, Type V PYGM AR Reduced Risk Glycogen Storage Disease, Type VII PFKM AR Reduced Risk HMG-CoA Lyase Deficiency HMGCL AR Reduced Risk Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Honocrystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria, cbE Type MTRR AR Reduced Risk Homocystinuria, cbE Type MTRR AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria, cbE Type MTRR AR Reduced Risk Hydrotethalus, Syndrome HYLS1 AR Reduced Risk Hyporornithinemia-Hyperamm		AGL	AR	Reduced Risk	
Glycogen Storage Disease, Type Ib SLC37A4 AR Reduced Risk Glycogen Storage Disease, Type V PYGM AR Reduced Risk Glycogen Storage Disease, Type VII PFKM AR Reduced Risk HMG-Co Lyase Deficiency HMGCL AR Reduced Risk Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS3 AR Reduced Risk Holocarboxylase Synthetase Deficiency HLCS AR Reduced Risk Homocystinuria Gue to MTH/FR Deficiency MTH/FR AR Reduced Risk Homocystinuria due to MTH/FR Deficiency MTH/R AR Reduced Risk Homocystinuria Cub E Type MTRR AR Reduced Risk Homocystinuria Syndrome HVLS1 AR Reduced Risk Hyporonthinemia-Hyperanmonemia- Hyporidritic Ectodermal Dysplasia 1 EDA XL Reduced Risk	Polyglucosan Body Disease				
Glycogen Storage Disease, Type V PYGM AR Reduced Risk Glycogen Storage Disease, Type VII PFKM AR Reduced Risk HMG-CoA Lyase Deficiency HMGCL AR Reduced Risk Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Herraditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Homocystinuria due to MTHR Deficiency HLCS AR Reduced Risk Homocystinuria due to MTHR Deficiency MTHR AR Reduced Risk Hydotothaluria a word on MTHR Deficiency MTHR AR Reduced Risk Hydotothaluria Syndrome HYLS1 AR Reduced Risk Hydotothaluria Syndrome HYLS1 AR Reduced Risk Hydrototic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypohosphatasia AL					
Glycogen Storage Disease, Type VII PFKM AR Reduced Risk HMG-CoA Lyase Deficiency HMGCL AR Reduced Risk Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Honcosystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria due to MTHFR Deficiency MTHFR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hydrolethalus Syndrome SLC25A15 AR Reduced Risk Hyperorithinemia-Hyperanmonemia- SLC25A15 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Inclusion Body Myopathy 2 GNE					
HMG-CoA Lyase Deficiency HMGCL AR Reduced Risk Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spatic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hemansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria, CBE Type MTRR AR Reduced Risk Hyperorithinemia-Hyperanmonemia- Hyperorithinemia-Hyperanmonemia- Homocitrullinuria Syndrome HYLS1 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hipperantmonemia- Homocitrullinuria Sindrome GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Infantile Cerebral Sis Int					
Hemochromatosis, Type 2A HFE2 AR Reduced Risk Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Hoocystinuria Gues Synthetase Deficiency HLCS AR Reduced Risk Homocystinuria Cues The THER Deficiency MTHER AR Reduced Risk Homocystinuria, cblE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperornithinemia-Hyperanmonemia- Hypohiotric Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypohosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Infantile Cerebral Risk <td></td> <td></td> <td></td> <td></td> <td></td>					
Hemochromatosis, Type 3 TFR2 AR Reduced Risk Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Holocarboxylase Synthetase Deficiency HLCS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria, cblE Type MTHFR AR Reduced Risk Homocystinuria, cblE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hydrolethalus Syndrome SLC25A15 AR Reduced Risk Hydrolethalus Syndrome MTLS1 AR Reduced Risk Hydrolethalus Syndrome MLD1 AR Reduced Risk Hydrolethalus Syndrome MLD2 AR Reduced Risk Inducition Body Myopathy 2 GNE AR Reduced Ris					
Hereditary Fructose Intolerance ALDOB AR Reduced Risk Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Honocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria, cbE Type MTRR AR Reduced Risk Homocystinuria, cbE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hypernithinemia-Hyperanmonemia-Hyperanmonemia-Hyperanmonemia-Hypernationeme SLC25A15 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Inclusion Body Myopathy 2 GINE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Inclusion Body Myopathy 2 GINE AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Inclusion Body Myopathy 2 GINE AR	••				
Hereditary Spastic Paraparesis 49 TECPR2 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Holocarboxylase Synthetase Deficiency HLCS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria due to MTHFR Deficiency MTHFR AR Reduced Risk Homocystinuria, cblE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperornithinemia-Hyperammonemia- Homocitrullinuria Syndrome HYLS1 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 3 RPGRiP1L AR Reduced Risk Junctional					
Hermansky-Pudlak Syndrome, Type 1 HPS1 AR Reduced Risk Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Holocarboxylase Synthetase Deficiency HLCS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria due to MTHFR Deficiency MTHFR AR Reduced Risk Homocystinuria, cblE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperonithinemia-Hyperammonemia- Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypophosphatasia ALPL AR Reduced Risk Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 3 LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk	•				
Hermansky-Pudlak Syndrome, Type 3 HPS3 AR Reduced Risk Holocarboxylase Synthetase Deficiency HLCS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria due to MTHFR Deficiency MTHFR AR Reduced Risk Homocystinuria, cblE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperornithinemia-Hyperanmonemia- Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypohotyptatisa 1 EDA XL Reduced Risk Hypohotyptatisa Hypohotyptatisa 2 GNE AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / RPGRIP1L AR Reduced Risk Joubert Syndrome LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- LAMB3 LAMB3 AR Reduced Risk					
Holocarboxylase Synthetase Deficiency HLCS AR Reduced Risk Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria due to MTHFR Deficiency MTHFR AR Reduced Risk Homocystinuria, cblE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hypeprornithinemia-Hyperanmonemia- Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypophorbitataia ALPL AR Reduced Risk Hypophorbitataia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk					
Homocystinuria (CBS-Related) CBS AR Reduced Risk Homocystinuria due to MTHFR Deficiency MTHFR AR Reduced Risk Homocystinuria, cblE Type MTR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperornithinemia-Hyperammonemia- Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infanile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk		-			
Homocystinuria due to MTHFR Deficiency MTHFR AR Reduced Risk Homocystinuria, cblE Type MTR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperornithinemia-Hyperammonemia- Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 3 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk					
Homocystinuria, cblE Type MTRR AR Reduced Risk Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperornithinemia-Hyperammonemia- Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Isovaleric Acidemia ND AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 3 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk	•				
Hydrolethalus Syndrome HYLS1 AR Reduced Risk Hyperornithinemia-Hyperammonemia- Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Isovaleric Acidemia N/D AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 3 RPGRIP1L AR Reduced Risk Joubert Syndrome 4 N/D AR Reduced Risk Joubert Syndrome 5 / COACH Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- LAMB3 AR Reduced Risk	• •			Reduced Risk	
Homocitrullinuria Syndrome SLC25A15 AR Reduced Risk Hypohidrotic Ectodermal Dysplasia 1 EDA XL Reduced Risk Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Isovaleric Acidemia ND AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk		HYLS1	AR		
Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Isovaleric Acidemia ND AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk		SLC25A15	AR	Reduced Risk	
Hypophosphatasia ALPL AR Reduced Risk Inclusion Body Myopathy 2 GNE AR Reduced Risk Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Isovaleric Acidemia ND AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk	•	EDA	XL	Reduced Risk	
Infantile Cerebral and Cerebellar Atrophy MED17 AR Reduced Risk Isovaleric Acidemia ND AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- LAMB3 AR Reduced Risk		ALPL			
Isovaleric Acidemia ND AR Reduced Risk Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- LAMB3 LAMB3 AR Reduced Risk	Inclusion Body Myopathy 2	GNE	AR	Reduced Risk	
Joubert Syndrome 2 TMEM216 AR Reduced Risk Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- Related) LAMB3 AR Reduced Risk	Infantile Cerebral and Cerebellar Atrophy	MED17	AR	Reduced Risk	
Joubert Syndrome 7 / Meckel Syndrome 5 / COACH Syndrome RPGRIP1L AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- Related) LAMB3 AR Reduced Risk	Isovaleric Acidemia	ND	AR	Reduced Risk	
COACH Syndrome RPGRIPIL AR Reduced Risk Junctional Epidermolysis Bullosa (LAMA3- Related) LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- LAMB3 LAMB3 AR Reduced Risk	Joubert Syndrome 2	TMEM216	AR	Reduced Risk	
Related) LAMA3 AR Reduced Risk Junctional Epidermolysis Bullosa (LAMB3- LAMB3 AR Reduced Risk		RPGRIP1L	AR	Reduced Risk	
	· · ·	LAMA3	AR	Reduced Risk	
	• •	LAMB3	AR	Reduced Risk	



Junctional Epidermolysis Bullosa (<i>LAMC2</i> - Related)	LAMC2	AR	Reduced Risk
Krabbe Disease	GALC	AR	Reduced Risk
Lamellar Ichthyosis, Type 1	TGM1	AR	Reduced Risk
Leber Congenital Amaurosis 10 and Other CEP290-Related Ciliopathies	CEP290	AR	Reduced Risk
Leber Congenital Amaurosis 13	RDH12	AR	Reduced Risk
Leber Congenital Amaurosis 2 / Retinitis	0050-	10	
Pigmentosa 20	RPE65	AR	Reduced Risk
Leber Congenital Amaurosis 5	LCA5	AR	Reduced Risk
Leber Congenital Amaurosis 8 / Retinitis			
Pigmentosa 12 / Pigmented Paravenous Chorioretinal Atrophy	CRB1	AR	Reduced Risk
Leigh Syndrome, French-Canadian Type	LRPPRC	AR	Reduced Risk
Lethal Congenital Contracture Syndrome 1 / Lethal Arthrogryposis with Anterior Horn Cell Disease	GLE1	AR	Reduced Risk
Leukoencephalopathy with Vanishing White Matter	EIF2B5	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2A	CAPN3	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2B	DYSF	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2C	SGCG	AR	Reduced Risk
Limb Girdle Muscular Dystrophy, Type 2D	SGCA	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 2E	SGCB	AR	Reduced Risk
Limb-Girdle Muscular Dystrophy, Type 21	FKRP	AR	Reduced Risk
Lipoamide Dehydrogenase Deficiency	DLD	AR	Reduced Risk
Lipoid Adrenal Hyperplasia	STAR	AR	Reduced Risk
Lipoprotein Lipase Deficiency	LPL	AR	Reduced Risk
Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency	HADHA	AR	Reduced Risk
Lysinuric Protein Intolerance	SLC7A7	AR	Reduced Risk
Maple Syrup Urine Disease, Type 1a	BCKDHA	AR	Reduced Risk
Maple Syrup Urine Disease, Type 1b	BCKDHB	AR	Reduced Risk
Meckel Syndrome 1 / Bardet-Biedl Syndrome 13	MKS1	AR	Reduced Risk
Medium Chain Acyl-CoA Dehydrogenase Deficiency	ACADM	AR	Reduced Risk
Megalencephalic Leukoencephalopathy with Subcortical Cysts	MLC1	AR	Reduced Risk
Menkes Disease	ATP7A	XL	Reduced Risk
Metachromatic Leukodystrophy	ARSA	AR	Reduced Risk
Methylmalonic Acidemia (MMAA-Related)	MMAA	AR	Reduced Risk
Methylmalonic Acidemia (MMAB-Related)	MMAB	AR	Reduced Risk
Methylmalonic Acidemia (MUT-Related)	MUT	AR	Reduced Risk
Methylmalonic Aciduria and Homocystinuria, Cobalamin C Type	MMACHC	AR	Reduced Risk
Methylmalonic Aciduria and Homocystinuria, Cobalamin D Type	MMADHC	AR	Reduced Risk
Microphthalmia / Anophthalmia	VSX2	AR	Reduced Risk
Mitochondrial Complex I Deficiency (<i>ACAD9</i> - Related)	ACAD9	AR	Reduced Risk
Mitochondrial Complex I Deficiency (<i>NDUFAF5</i> - Related)	NDUFAF5	AR	Reduced Risk
Mitochondrial Complex I Deficiency (<i>NDUFS6</i> - Related)	NDUFS6	AR	Reduced Risk
Mitochondrial DNA Depletion Syndrome 6 / Navajo Neurohepatopathy	MPV17	AR	Reduced Risk
Mitochondrial Myopathy and Sideroblastic Anemia 1	PUS1	AR	Reduced Risk
Mucolipidosis II / IIIA	GNPTAB	AR	Reduced Risk
Mucolipidosis III Gamma	GNPTG	AR	Reduced Risk
Mucolipidosis IV	MCOLN1	AR	Reduced Risk
Mucopolysaccharidosis Type I	IDUA	AR	Reduced Risk
Mucopolysaccharidosis Type II	IDS	XL	Reduced Risk
Mucopolysaccharidosis Type IIIA	SGSH	AR	Reduced Risk
Mucopolysaccharidosis Type IIIB	NAGLU	AR	Reduced Risk

T: 800-298-6470 F: 646-859-6870 www.sema4.com



Mucopolysaccharidosis Type IIIC	HGSNAT	AR	Reduced Risk
Mucopolysaccharidosis Type IIID	GNS	AR	Reduced Risk
Mucopolysaccharidosis Type IVb / GM1 Gangliosidosis	GLB1	AR	Reduced Risk
Mucopolysaccharidosis type IX	HYAL1	AR	Reduced Risk
Mucopolysaccharidosis type VI	ARSB	AR	Reduced Risk
Multiple Sulfatase Deficiency	SUMF1	AR	Reduced Risk
Muscle-Eye-Brain Disease and Other <i>POMGNT</i> 1- Related Congenital Muscular Dystrophy-	POMGNT1	AR	Reduced Risk
Dystroglycanopathies	TYMP	AR	Reduced Risk
Myoneurogastrointestinal Encephalopathy			
Myotubular Myopathy 1	MTM1	XL	Reduced Risk
N-Acetylglutamate Synthase Deficiency	NAGS	AR	Reduced Risk
Nemaline Myopathy 2	NEB	AR	Reduced Risk
Nephrogenic Diabetes Insipidus, Type II	AQP2	AR	Reduced Risk
Nephrotic Syndrome (<i>NPHS1</i> -Related) / Congenital Finnish Nephrosis	NPHS1	AR	Reduced Risk
Nephrotic Syndrome (<i>NPHS2</i> -Related) / Steroid-Resistant Nephrotic Syndrome	NPHS2	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN3-Related)	CLN3	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN5-Related)	CLN5	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN6-Related)	CLN6	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (CLN8-Related)	CLN8	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (<i>MFSD8-</i> Related)	MFSD8	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (PPT1-Related)	PPT1	AR	Reduced Risk
Neuronal Ceroid-Lipofuscinosis (TPP1-Related)	TPP1	AR	Reduced Risk
Niemann-Pick Disease (<i>SMPD1</i> -Related)	SMPD1	AR	Reduced Risk
Niemann-Pick Disease, Type C (<i>NPC1</i> -Related)	NPC1	AR	Reduced Risk
Niemann-Pick Disease, Type C (<i>NPC2</i> -Related)	NPC2	AR	Reduced Risk
Nijmegen Breakage Syndrome	NBN	AR	Reduced Risk
Non-Syndromic Hearing Loss (<i>GJB2</i> -Related)	GJB2	AR	Reduced Risk
Odonto-Onycho-Dermal Dysplasia / Schopf- Schulz-Passarge Syndrome	WNT10A	AR	Reduced Risk
Omenn Syndrome (<i>RAG2</i> -Related)	RAG2	AR	Reduced Risk
Omenn Syndrome / Severe Combined	DCLRE1C	AR	Reduced Risk
Immunodeficiency, Athabaskan-Type	OAT	4.0	Paducad Dick
Ornithine Aminotransferase Deficiency		AR	Reduced Risk
Ornithine Transcarbamylase Deficiency	OTC	XL	Reduced Risk
Osteopetrosis 1	TCIRG1	AR	Reduced Risk
Pendred Syndrome	SLC26A4		
•		AR	Reduced Risk
Phenylalanine Hydroxylase Deficiency	PAH	AR	Reduced Risk Reduced Risk
Phenylalanine Hydroxylase Deficiency Polycystic Kidney Disease, Autosomal Recessive	PAH PKHD1		
Polycystic Kidney Disease, Autosomal		AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive	PKHD1	AR AR	Reduced Risk Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1	PKHD1 AIRE	AR AR AR	Reduced Risk Reduced Risk Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A	PKHD1 AIRE VRK1	AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6	PKHD1 AIRE VRK1 RARS2	AR AR AR AR AR	Reduced Risk Reduced Risk Reduced Risk Reduced Risk Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency	PKHD1 AIRE VRK1 RARS2 SLC22A5	AR AR AR AR AR AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related)	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5	AR AR AR AR AR AR AR AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI1-Related)	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAI1	AR AR AR AR AR AR AR AR AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI1-Related) Primary Ciliary Dyskinesia (DNAI2-Related)	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAI1 DNAI2	AR AR AR AR AR AR AR AR AR AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 2	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAI1 DNAI2 AGXT GRHPR	AR AR AR AR AR AR AR AR AR AR AR AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 3	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAI1 DNAI2 AGXT GRHPR HOGA1	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 2 Primary Hyperoxaluria, Type 3 Progressive Cerebello-Cerebral Atrophy Progressive Familial Intrahepatic Cholestasis,	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAI1 DNAI2 AGXT GRHPR	AR AR AR AR AR AR AR AR AR AR AR AR	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 2 Primary Hyperoxaluria, Type 3 Progressive Cerebello-Cerebral Atrophy Progressive Familial Intrahepatic Cholestasis, Type 2	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAI2 AGXT GRHPR HOGA1 SEPSECS ABCB11	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk
Polycystic Kidney Disease, Autosomal RecessivePolyglandular Autoimmune Syndrome, Type 1Pontocerebellar Hypoplasia, Type 1APontocerebellar Hypoplasia, Type 6Primary Carnitine DeficiencyPrimary Ciliary Dyskinesia (DNAH5-Related)Primary Ciliary Dyskinesia (DNAI2-Related)Primary Ciliary Dyskinesia (DNAI2-Related)Primary Hyperoxaluria, Type 1Primary Hyperoxaluria, Type 2Primary Hyperoxaluria, Type 3Progressive Cerebello-Cerebral AtrophyProgressive Familial Intrahepatic Cholestasis, Type 2Propionic Acidemia (PCCA-Related)	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAI2 AGXT GRHPR HOGA1 SEPSECS ABCB11 PCCA	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 2 Primary Hyperoxaluria, Type 3 Progressive Cerebello-Cerebral Atrophy Progressive Familial Intrahepatic Cholestasis, Type 2 Propionic Acidemia (PCCA-Related) Propionic Acidemia (PCCB-Related)	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAI2 AGXT GRHPR HOGA1 SEPSECS ABCB11 PCCA PCCB	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 2 Primary Hyperoxaluria, Type 3 Progressive Cerebello-Cerebral Atrophy Progressive Familial Intrahepatic Cholestasis, Type 2 Propionic Acidemia (PCCA-Related) Propionic Acidemia (PCCB-Related) Pycnodysostosis	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAH2 DNAI2 AGXT GRHPR HOGA1 SEPSECS ABCB11 PCCA PCCB CTSK	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 2 Progressive Cerebello-Cerebral Atrophy Progressive Familial Intrahepatic Cholestasis, Type 2 Propionic Acidemia (PCCA-Related) Propionic Acidemia (PCCB-Related) Pycnodysostosis Pyruvate Dehydrogenase E1-Alpha Deficiency	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAH2 AGXT GRHPR HOGA1 SEPSECS ABCB11 PCCA PCCB CTSK PDHA1	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk Reduced Risk
Polycystic Kidney Disease, Autosomal Recessive Polyglandular Autoimmune Syndrome, Type 1 Pontocerebellar Hypoplasia, Type 1A Pontocerebellar Hypoplasia, Type 6 Primary Carnitine Deficiency Primary Ciliary Dyskinesia (DNAH5-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Ciliary Dyskinesia (DNAI2-Related) Primary Hyperoxaluria, Type 1 Primary Hyperoxaluria, Type 2 Primary Hyperoxaluria, Type 3 Progressive Cerebello-Cerebral Atrophy Progressive Familial Intrahepatic Cholestasis, Type 2 Propionic Acidemia (PCCA-Related) Propionic Acidemia (PCCB-Related) Pycnodysostosis	PKHD1 AIRE VRK1 RARS2 SLC22A5 DNAH5 DNAH5 DNAH2 DNAI2 AGXT GRHPR HOGA1 SEPSECS ABCB11 PCCA PCCB CTSK	AR AR AR AR AR AR AR AR AR AR AR AR AR A	Reduced Risk



Retinitis Pigmentosa 25	EYS	AR	Reduced Risk	
Retinitis Pigmentosa 26	CERKL	AR	Reduced Risk	
Retinitis Pigmentosa 28	FAM161A	AR	Reduced Risk	
Retinitis Pigmentosa 59	DHDDS	AR	Reduced Risk	
Rhizomelic Chondrodysplasia Punctata, Type 1	PEX7	AR	Reduced Risk	
Rhizomelic Chondrodysplasia Punctata, Type 3	AGPS	AR	Reduced Risk	
Roberts Syndrome	ESCO2	AR	Reduced Risk	
Salla Disease	SLC17A5	AR	Reduced Risk	
Sandhoff Disease	HEXB	AR	Reduced Risk	
Schimke Immunoosseous Dysplasia	SMARCAL1	AR	Reduced Risk	
Segawa Syndrome	TH	AR	Reduced Risk	
Sjogren-Larsson Syndrome	ALDH3A2	AR	Reduced Risk	
Smith-Lemli-Opitz Syndrome	DHCR7	AR	Reduced Risk	
Spinal Muscular Atrophy	SMN1	AR	Reduced Risk	<i>SMN1</i> copy number: 2 <i>SMN2</i> copy number: 1 c.*3+80T>G: Negative
Spondylothoracic Dysostosis	MESP2	AR	Reduced Risk	
Steel Syndrome	COL27A1	AR	Reduced Risk	
Stuve-Wiedemann Syndrome	LIFR	AR	Reduced Risk	
Sulfate Transporter-Related Osteochondrodysplasia	SLC26A2	AR	Reduced Risk	
Tay-Sachs Disease	HEXA	AR	Reduced Risk	
Tyrosinemia, Type I	FAH	AR	Reduced Risk	
Usher Syndrome, Type IB	MYO7A	AR	Reduced Risk	
Usher Syndrome, Type IC	USH1C	AR	Reduced Risk	
Usher Syndrome, Type ID	CDH23	AR	Reduced Risk	
Usher Syndrome, Type IF	PCDH15	AR	Reduced Risk	
Usher Syndrome, Type IIA	USH2A	AR	Reduced Risk	
Usher Syndrome, Type III	CLRN1	AR	Reduced Risk	
Very Long Chain Acyl-CoA Dehydrogenase Deficiency	ACADVL	AR	Reduced Risk	
Walker-Warburg Syndrome and Other <i>FKTN</i> - Related Dystrophies	FKTN	AR	Reduced Risk	
Wilson Disease	ATP7B	AR	Reduced Risk	
Wolman Disease / Cholesteryl Ester Storage Disease	LIPA	AR	Reduced Risk	
X-Linked Juvenile Retinoschisis	RS1	XL	Reduced Risk	
X-Linked Severe Combined Immunodeficiency	IL2RG	XL	Reduced Risk	
Zellweger Syndrome Spectrum (<i>PEX10</i> -Related)	PEX10	AR	Reduced Risk	
Zellweger Syndrome Spectrum (<i>PEX1</i> -Related)	PEX1	AR	Reduced Risk	
Zellweger Syndrome Spectrum (<i>PEX2</i> -Related)	PEX2	AR	Reduced Risk	
Zellweger Syndrome Spectrum (PEX6-Related)	PEX6	AR	Reduced Risk	

AR=Autosomal recessive; XL=X-linked

Test methods and comments

Genomic DNA isolated from this patient was analyzed by one or more of the following methodologies, as applicable:

Fragile X CGG Repeat Analysis (Analytical Detection Rate >99%)

PCR amplification using Asuragen, Inc. AmplideX[®]*FMR1* PCR reagents followed by capillary electrophoresis for allele sizing was performed. Samples positive for *FMR1* CGG repeats in the premutation and full mutation size range were further analyzed by Southern blot analysis to assess the size and methylation status of the *FMR1* CGG repeat.

Genotyping (Analytical Detection Rate >99%)

Multiplex PCR amplification and allele specific primer extension analyses using the MassARRAY[®] System were used to identify certain recurrent variants that are complex in nature or are present in low copy repeats. Rare sequence variants may interfere with assay performance.

Multiplex Ligation-Dependent Probe Amplification (MLPA) (Analytical Detection Rate >99%)

MLPA[®] probe sets and reagents from MRC-Holland were used for copy number analysis of specific targets versus known control samples. False positive or negative results may occur due to rare sequence variants in target regions detected by MLPA probes. Analytical sensitivity and specificity of the MLPA method are both 99%.



Carrier screening report Donor 6508 Date of Birth: Sema4 ID

For alpha thalassemia, the copy numbers of the *HBA1* and *HBA2* genes were analyzed. Alpha-globin gene deletions, triplications, and the Constant Spring (CS) mutation are assessed. This test is expected to detect approximately 90% of all alpha-thalassemia mutations, varying by ethnicity. carriers of alpha-thalassemia with three or more *HBA* copies on one chromosome, and one or no copies on the other chromosome, may not be detected. With the exception of triplications, other benign alpha-globin gene polymorphisms will not be reported. Analyses of *HBA1* and *HBA2* are performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For Duchenne muscular dystrophy, the copy numbers of all *DMD* exons were analyzed. Potentially pathogenic single exon deletions and duplications are confirmed by a second method. Analysis of *DMD* is performed in association with sequencing of the coding regions.

For congenital adrenal hyperplasia, the copy number of the *CYP21A2* gene was analyzed. This analysis can detect large deletions typically due to unequal meiotic crossing-over between *CYP21A2* and the pseudogene *CYP21A1P*. Classic 30-kb deletions make up approximately 20% of *CYP21A2* pathogenic alleles. This test may also identify certain point mutations in *CYP21A2* caused by gene conversion events between *CYP21A2* and *CYP21A2* and *CYP21A1P*. Some carriers may not be identified by dosage sensitive methods as this testing cannot detect individuals with two copies (duplication) of the *CYP21A2* gene on one chromosome and loss of *CYP21A2* (deletion) on the other chromosome. Analysis of *CYP21A2* is performed in association with long-range PCR of the coding regions followed by short-read sequencing.

For spinal muscular atrophy (SMA), the copy numbers of the *SMN1* and *SMN2* genes were analyzed. The individual dosage of exons 7 and 8 as well as the combined dosage of exons 1, 4, 6 and 8 of *SMN1* and *SMN2* were assessed. Copy number gains and losses can be detected with this assay. Depending on ethnicity, 6 - 29 % of carriers will not be identified by dosage sensitive methods as this testing cannot detect individuals with two copies (duplication) of the *SMN1* gene on one chromosome and loss of *SMN1* (deletion) on the other chromosome (silent 2+0 carrier) or individuals that carry an intragenic mutation in *SMN1*. Please also note that 2% of individuals diagnosed with SMA have a causative *SMN1* variant that occurred *de novo*, and therefore cannot be picked up by carrier screening in the parents. Analysis of *SMN1* is performed in association with short-read sequencing of exons 2a-7, followed by confirmation using long-range PCR (described below). The presence of the c.*3+80T>G (chr5:70,247,901T>G) variant allele in an individual with Ashkenazi Jewish or Asian ancestry is typically indicative of a duplication of *SMN1*. When present in an Ashkenazi Jewish or Asian individual with two copies of *SMN1*, c.*3+80T>G is likely indicative of a silent (2+0) carrier. In individuals with two copies of *SMN1* with African American, Hispanic or Caucasian ancestry, the presence or absence of c.*3+80T>G significantly increases or decreases, respectively, the likelihood of being a silent 2+0 silent carrier.

MLPA for Gaucher disease (*GBA*), cystic fibrosis (*CFTR*), and non-syndromic hearing loss (*GJB2/GJB6*) will only be performed if indicated for confirmation of detected CNVs. If *GBA* analysis was performed, the copy numbers of exons 1, 3, 4, and 6 - 10 of the *GBA* gene (of 11 exons total) were analyzed. If *CFTR* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy numbers of all 27 *CFTR* exons were analyzed. If *GJB2/GJB6* analysis was performed, the copy number of the two *GJB2* exons were analyzed, as well as the presence or absence of the two upstream deletions of the *GJB2* regulatory region, del(*GJB6*-D13S1830) and del(*GJB6*-D13S1854).

Next Generation Sequencing (NGS) (Analytical Detection Rate >95%)

NGS was performed on a panel of genes for the purpose of identifying pathogenic or likely pathogenic variants.

Agilent SureSelectTMXT Low Input technology was used with a custom capture library to target the exonic regions and intron/exon splice junctions of the relevant genes, as well as a number of UTR, intronic or promoter regions that contain previously reported mutations. Libraries were pooled and sequenced on the Illumina NovaSeq 9000 platform, using paired-end 100 bp reads. The sequencing data was analyzed using a custom bioinformatics algorithm designed and validated in house.

The coding exons and splice junctions of the known protein-coding RefSeq genes were assessed for the average depth of coverage (minimum of 20X) and data quality threshold values. Most exons not meeting a minimum of >20X read depth across the exon are further analyzed by Sanger sequencing. Please note that several genomic regions present difficulties in mapping or obtaining read depth >20X. These regions, which are described below, will not be reflexed to Sanger sequencing if the mapping quality or coverage is poor. Any variants identified during testing in these regions are confirmed by a second method and reported if determined to be pathogenic or likely pathogenic. However, as there is a possibility of false negative results within these regions, detection rates and residual risks for these genes have been calculated with the

presumption that variants in these exons will not be detected, unless included in the MassARRAY[®] genotyping platform.

Exceptions: ABCD1 (NM_000033.3) exons 8 and 9; *ADA* (NM_000022.2) exon 1; *ADAMTS2* (NM_014244.4) exon 1; *AGPS* (NM_003659.3) chr2:178.257.512 - 178.257.649 (partial exon 1); *ALMS1* (NM_015120.4) chr2:73.612.990 - 73.613.041 (partial exon 1); *CEP290* (NM_025114.3) exon 5, exon 7, chr12:88.519.017 - 88.519.039 (partial exon 13), chr12:88.514.049 - 88.514.058 (partial exon 15), chr12:88.502.837 - 88.502.841 (partial exon 23), chr12:88.481.551 - 88.481.559 (partial exon 32), chr12:88.471.605 - 88.471.700 (partial exon 40); *CFTR* (NM_000492.3) exon 10; *COL4A4* (NM_000092.4) chr2:227.942.604 - 227.942.619 (partial exon 25); *CYP11B2* (NM_000498.3) exons 3 - 7; *DNAl2* (NM_023036.4) chr17:72.308.136 - 72.308.147 (partial exon 12); *EVC* (NM_1537172) exon 1; *FH* (NM_000143.3) exon 1; *GAMT* (NM_000156.5 exon 1; *GLDC* (NM_000170.2) exon 1; *GNPTAB* (NM_024312.4) chr17:4.837.000 - 4.837.400 (partial exon 2); *GNPTG* (NM_032520.4) exon 1; *HGSNAT* (NM_152419.2) exon 1; *IDS* (NM_000202.6) exon 3; *LIFR* (NM_002310.5) exon 19; *NEB* (NM_001271208.1) exons 82 - 105; *NPC1* (NM_000271.4) chr18:21.123.519 - 21.123.538



(partial exon 14); *PUS1* (NM_025215.5) ; chr12:132,414,446 - 132,414,532 (partial exon 2); *RPGRIP1L* (NM_015272.2) exon 23; *SGSH* (NM_000199.3) chr17:78,194,022 - 78,194,072 (partial exon 1); *SLC6A8* (NM_005629.3) exons 3 and 4.

This test will detect variants within the exons and the intron-exon boundaries of the target regions. Variants outside these regions may not be detected, including, but not limited to, UTRs, promoters, and deep intronic areas, or regions that fall into the Exceptions mentioned above. This technology may not detect all small insertion/deletions and is not diagnostic for repeat expansions and structural genomic variation. In addition, a mutation(s) in a gene not included on the panel could be present in this patient.

Variant interpretation and classification was performed based on the American College of Medical Genetics Standards and Guidelines for the Interpretation of Sequence Variants (Richards et al. 2015). All potentially pathogenic variants may be confirmed by either a specific genotyping assay or Sanger sequencing, if indicated. Any benign variants, likely benign variants or variants of uncertain significance identified during this analysis will not be reported.

Next Generation Sequencing for SMN1

Exonic regions and intron/exon splice junctions of *SMN1* and *SMN2* were captured, sequenced, and analyzed as described above. Any variants located within exons 2a-7 and classified as pathogenic or likely pathogenic were confirmed to be in either *SMN1* or *SMN2* using gene-specific long-range PCR analysis followed by Sanger sequencing. Variants located in exon 1 cannot be accurately assigned to either *SMN1* or *SMN2* using our current methodology, and so these variants are considered to be of uncertain significance and are not reported.

Copy Number Variant Analysis (Analytical Detection Rate >95%)

Large duplications and deletions were called from the relative read depths on an exon-by-exon basis using a custom exome hidden Markov model (XHMM) algorithm. Deletions or duplications determined to be pathogenic or likely pathogenic were confirmed by either a custom arrayCGH platform, quantitative PCR, or MLPA (depending on CNV size and gene content). While this algorithm is designed to pick up deletions and duplications of 2 or more exons in length, potentially pathogenic single-exon CNVs will be confirmed and reported, if detected.

Exon Array (Confirmation method) (Accuracy >99%)

The customized oligonucleotide microarray (Oxford Gene Technology) is a highly-targeted exon-focused array capable of detecting medically relevant microdeletions and microduplications at a much higher resolution than traditional aCGH methods. Each array matrix has approximately 180,000 60-mer oligonucleotide probes that cover the entire genome. This platform is designed based on human genome NCBI Build 37 (hg19) and the CGH probes are enriched to target the exonic regions of the genes in this panel.

Quantitative PCR (Confirmation method) (Accuracy >99%)

The relative quantification PCR is utilized on a Roche Universal Library Probe (UPL) system, which relates the PCR signal of the target region in one group to another. To test for genomic imbalances, both sample DNA and reference DNA is amplified with primer/probe sets that specific to the target region and a control region with known genomic copy number. Relative genomic copy numbers are calculated based on the standard $\Delta\Delta$ Ct formula.

Long-Range PCR (Analytical Detection Rate >99%)

Long-range PCR was performed to generate locus-specific amplicons for *CYP21A2, HBA1* and *HBA2* and *GBA*. The PCR products were then prepared for short-read NGS sequencing and sequenced. Sequenced reads were mapped back to the original genomic locus and run through the bioinformatics pipeline. If indicated, copy number from MLPA was correlated with the sequencing output to analyze the results. For *CYP21A2*, a certain percentage of healthy individuals carry a duplication of the *CYP21A2* gene, which has no clinical consequences. In cases where two copies of a gene are located on the same chromosome in tandem, only the second copy will be amplified and assessed for potentially pathogenic variants, due to size limitations of the PCR reaction. However, because these alleles contain at least two copies of the *CYP21A2* gene in tandem, it is expected that this patient has at least one functional gene in the tandem allele and this patient is therefore less likely to be a carrier. When an individual carries both a duplication allele and a pathogenic variant, or multiple pathogenic variants, the current analysis may not be able to determine the phase (cis/trans configuration) of the *CYP21A2* alleles identified. Family studies may be required in certain scenarios where phasing is required to determine the carrier status.

Residual Risk Calculations

Carrier frequencies and detection rates for each ethnicity were calculated trough the combination of internal curations of >30,000 variants and genomic frequency data from >138,000 individuals across seven ethnic groups in the gnomAD database. Additional variants in HGMD and novel deleterious variants were also incorporated into the calculation. Residual risk values are calculated using a Bayesian analysis combining the *a priori* risk of being a pathogenic mutation carrier (carrier frequency) and the detection rate. They are provided only as a guide for assessing approximate risk given a negative result, and values will vary based on the exact ethnic background of an individual. This report does not represent medical advice but should be interpreted by a genetic counselor, medical geneticist or physician skilled in genetic result interpretation and the relevant medical literature.

Personalized Residual Risk Calculations



Agilent SureSelectTMXT Low-Input technology was utilized in order to create whole-genome libraries for each patient sample. Libraries were then pooled and sequenced on the Illumina NovaSeq platform. Each sequencing lane was multiplexed to achieve 0.4-2x genome coverage, using paired-end 100 bp reads. The sequencing data underwent ancestral analysis using a customized, licensed bioinformatics algorithm that was validated in house. Identified sub-ethnic groupings were binned into one of 7 continental-level groups (African, East Asian, South Asian, Non-Finnish European, Finnish, Native American, and Ashkenazi Jewish) or, for those ethnicities that matched poorly to the continental-level groups, an 8th "unassigned" group, which were then used to select residual risk values for each gene. For individuals belonging to multiple high-level ethnic groupings, a weighting strategy was used to select the most appropriate residual risk. For genes that had insufficient data to calculate ethnic-specific residual risk values, or for sub-ethnic groupings that fell into the "unassigned" group, a "worldwide" residual risk was used. This "worldwide" residual risk was calculated using data from all available continental-level groups.

Sanger Sequencing (Confirmation method) (Accuracy >99%)

Sanger sequencing, as indicated, was performed using BigDye Terminator chemistry with the ABI 3730 DNA analyzer with target specific amplicons. It also may be used to supplement specific guaranteed target regions that fail NGS sequencing due to poor quality or low depth of coverage (<20 reads) or as a confirmatory method for NGS positive results. False negative results may occur if rare variants interfere with amplification or annealing.

Please note these tests were developed and their performance characteristics were determined by Mount Sinai Genomics, Inc. They have not been cleared or approved by the FDA. These analyses generally provide highly accurate information regarding the patient's carrier or affected status. Despite this high level of accuracy, it should be kept in mind that there are many potential sources of diagnostic error, including misidentification of samples, polymorphisms, or other rare genetic variants that interfere with analysis. Families should understand that rare diagnostic errors may occur for these reasons.

SELECTED REFERENCES

Carrier Screening

Grody W et al. ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013 15:482-3.

Fragile X syndrome:

Chen L et al. An information-rich CGG repeat primed PCR that detects the full range of Fragile X expanded alleles and minimizes the need for Southern blot analysis. *J Mol Diag* 2010 12:589-600.

Spinal Muscular Atrophy:

Luo M et al. An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. *Genet Med.* 2014 16:149-56.

Ashkenazi Jewish Disorders:

Scott SA et al. Experience with carrier screening and prenatal diagnosis for sixteen Ashkenazi Jewish Genetic Diseases. *Hum. Mutat.* 2010 31:1-11.

Duchenne Muscular Dystrophy:

Flanigan KM et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Hum Mutat.* 2009 30:1657-66.

Variant Classification:

Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May;17(5):405-24 Additional disease-specific references available upon request.